Loading…

Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells

Previous studies have demonstrated that verapamil may overcome resistance to anthracyclines. In vitro and in vivo experiments were performed on wild-type and resistant Ehrlich ascites tumor cells. Verapamil in concentrations of 25-50 microM enhances the accumulation of daunorubicin (DNR) in resistan...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 1987-01, Vol.19 (1), p.35-39
Main Authors: FRICHE, E, SKOVSGAARD, T, NISSEN, N. I
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c311t-7c4ee81de0402541a02d37acae792e0ea2cf3203c83e450c98628e6e07eacc253
cites cdi_FETCH-LOGICAL-c311t-7c4ee81de0402541a02d37acae792e0ea2cf3203c83e450c98628e6e07eacc253
container_end_page 39
container_issue 1
container_start_page 35
container_title Cancer chemotherapy and pharmacology
container_volume 19
creator FRICHE, E
SKOVSGAARD, T
NISSEN, N. I
description Previous studies have demonstrated that verapamil may overcome resistance to anthracyclines. In vitro and in vivo experiments were performed on wild-type and resistant Ehrlich ascites tumor cells. Verapamil in concentrations of 25-50 microM enhances the accumulation of daunorubicin (DNR) in resistant cells to the same level as in wild-type cells. No significant effect of verapamil on influx or nuclear binding could be demonstrated, indicating that verapamil enhances DNR uptake by blocking active drug extrusion. Exposure of cells to a high concentration of Ca2+ did not influence the effect of verapamil on DNR accumulation, suggesting a different mode of verapamil action apart from the Ca2+-blocking effect. Attempts to circumvent acquired resistance to DNR in vivo with verapamil showed that the combination of the two drugs was more toxic than DNR given alone. The LD10 of DNR was determined as 3 mg/kg and the LD10 of the combination, as 2.5 mg/kg. The therapeutic effect of verapamil at a dose of 50 mg/kg and DNR of 2.5 mg/kg increased the life span of the mice by 50%. No difference was seen in the wild-type tumor in vivo. These data lead us to conclude that verapamil can reverse DNR resistance completely, but that verapamil at non-toxic dosage only reduces DNR resistance by 50% in vivo.
doi_str_mv 10.1007/BF00296252
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00296252</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3815723</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-7c4ee81de0402541a02d37acae792e0ea2cf3203c83e450c98628e6e07eacc253</originalsourceid><addsrcrecordid>eNpFkE1Lw0AQhhdRaq1evAt78CREZz-S3Ry1tCoUetFz2E4mdCUfZTcR_PdGGuppGN6Hl5mHsVsBjwLAPL2sAWSeyVSesbnQSiZgtTpnc1BaJ6kBfcmuYvwCAC2UmrGZsiI1Us3ZdlVVhD3vKv5NwR1c42vetbx0Q9uFYefRt9whDs1Qu96Pybiv9qH2uOcuou8p8n5ousCR6jpes4vK1ZFuprlgn-vVx_It2Wxf35fPmwSVEH1iUBNZURJokKkWDmSpjENHJpcE5CRWSoJCq0ingLnNpKWMwNB4jEzVgj0cezF0MQaqikPwjQs_hYDiT0rxL2WE747wYdg1VJ7QycKY30_5-JGrq-Ba9PGEWQk2g1z9AvHQaN0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells</title><source>SpringerLink Online Journals Archive Complete</source><creator>FRICHE, E ; SKOVSGAARD, T ; NISSEN, N. I</creator><creatorcontrib>FRICHE, E ; SKOVSGAARD, T ; NISSEN, N. I</creatorcontrib><description>Previous studies have demonstrated that verapamil may overcome resistance to anthracyclines. In vitro and in vivo experiments were performed on wild-type and resistant Ehrlich ascites tumor cells. Verapamil in concentrations of 25-50 microM enhances the accumulation of daunorubicin (DNR) in resistant cells to the same level as in wild-type cells. No significant effect of verapamil on influx or nuclear binding could be demonstrated, indicating that verapamil enhances DNR uptake by blocking active drug extrusion. Exposure of cells to a high concentration of Ca2+ did not influence the effect of verapamil on DNR accumulation, suggesting a different mode of verapamil action apart from the Ca2+-blocking effect. Attempts to circumvent acquired resistance to DNR in vivo with verapamil showed that the combination of the two drugs was more toxic than DNR given alone. The LD10 of DNR was determined as 3 mg/kg and the LD10 of the combination, as 2.5 mg/kg. The therapeutic effect of verapamil at a dose of 50 mg/kg and DNR of 2.5 mg/kg increased the life span of the mice by 50%. No difference was seen in the wild-type tumor in vivo. These data lead us to conclude that verapamil can reverse DNR resistance completely, but that verapamil at non-toxic dosage only reduces DNR resistance by 50% in vivo.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/BF00296252</identifier><identifier>PMID: 3815723</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Animals ; Antineoplastic agents ; Biological and medical sciences ; Biological Transport, Active - drug effects ; Calcium - pharmacology ; Carcinoma, Ehrlich Tumor - metabolism ; Carcinoma, Ehrlich Tumor - pathology ; Cell Line ; Daunorubicin - metabolism ; Daunorubicin - toxicity ; Dose-Response Relationship, Drug ; Drug Resistance ; Drug Synergism ; Female ; General aspects ; Glucose - pharmacology ; Medical sciences ; Mice ; Mice, Inbred Strains ; Pharmacology. Drug treatments ; Stimulation, Chemical ; Verapamil - pharmacology ; Verapamil - toxicity</subject><ispartof>Cancer chemotherapy and pharmacology, 1987-01, Vol.19 (1), p.35-39</ispartof><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-7c4ee81de0402541a02d37acae792e0ea2cf3203c83e450c98628e6e07eacc253</citedby><cites>FETCH-LOGICAL-c311t-7c4ee81de0402541a02d37acae792e0ea2cf3203c83e450c98628e6e07eacc253</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=8208609$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3815723$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FRICHE, E</creatorcontrib><creatorcontrib>SKOVSGAARD, T</creatorcontrib><creatorcontrib>NISSEN, N. I</creatorcontrib><title>Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><description>Previous studies have demonstrated that verapamil may overcome resistance to anthracyclines. In vitro and in vivo experiments were performed on wild-type and resistant Ehrlich ascites tumor cells. Verapamil in concentrations of 25-50 microM enhances the accumulation of daunorubicin (DNR) in resistant cells to the same level as in wild-type cells. No significant effect of verapamil on influx or nuclear binding could be demonstrated, indicating that verapamil enhances DNR uptake by blocking active drug extrusion. Exposure of cells to a high concentration of Ca2+ did not influence the effect of verapamil on DNR accumulation, suggesting a different mode of verapamil action apart from the Ca2+-blocking effect. Attempts to circumvent acquired resistance to DNR in vivo with verapamil showed that the combination of the two drugs was more toxic than DNR given alone. The LD10 of DNR was determined as 3 mg/kg and the LD10 of the combination, as 2.5 mg/kg. The therapeutic effect of verapamil at a dose of 50 mg/kg and DNR of 2.5 mg/kg increased the life span of the mice by 50%. No difference was seen in the wild-type tumor in vivo. These data lead us to conclude that verapamil can reverse DNR resistance completely, but that verapamil at non-toxic dosage only reduces DNR resistance by 50% in vivo.</description><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biological Transport, Active - drug effects</subject><subject>Calcium - pharmacology</subject><subject>Carcinoma, Ehrlich Tumor - metabolism</subject><subject>Carcinoma, Ehrlich Tumor - pathology</subject><subject>Cell Line</subject><subject>Daunorubicin - metabolism</subject><subject>Daunorubicin - toxicity</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Resistance</subject><subject>Drug Synergism</subject><subject>Female</subject><subject>General aspects</subject><subject>Glucose - pharmacology</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred Strains</subject><subject>Pharmacology. Drug treatments</subject><subject>Stimulation, Chemical</subject><subject>Verapamil - pharmacology</subject><subject>Verapamil - toxicity</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><recordid>eNpFkE1Lw0AQhhdRaq1evAt78CREZz-S3Ry1tCoUetFz2E4mdCUfZTcR_PdGGuppGN6Hl5mHsVsBjwLAPL2sAWSeyVSesbnQSiZgtTpnc1BaJ6kBfcmuYvwCAC2UmrGZsiI1Us3ZdlVVhD3vKv5NwR1c42vetbx0Q9uFYefRt9whDs1Qu96Pybiv9qH2uOcuou8p8n5ousCR6jpes4vK1ZFuprlgn-vVx_It2Wxf35fPmwSVEH1iUBNZURJokKkWDmSpjENHJpcE5CRWSoJCq0ingLnNpKWMwNB4jEzVgj0cezF0MQaqikPwjQs_hYDiT0rxL2WE747wYdg1VJ7QycKY30_5-JGrq-Ba9PGEWQk2g1z9AvHQaN0</recordid><startdate>19870101</startdate><enddate>19870101</enddate><creator>FRICHE, E</creator><creator>SKOVSGAARD, T</creator><creator>NISSEN, N. I</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19870101</creationdate><title>Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells</title><author>FRICHE, E ; SKOVSGAARD, T ; NISSEN, N. I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-7c4ee81de0402541a02d37acae792e0ea2cf3203c83e450c98628e6e07eacc253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biological Transport, Active - drug effects</topic><topic>Calcium - pharmacology</topic><topic>Carcinoma, Ehrlich Tumor - metabolism</topic><topic>Carcinoma, Ehrlich Tumor - pathology</topic><topic>Cell Line</topic><topic>Daunorubicin - metabolism</topic><topic>Daunorubicin - toxicity</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Resistance</topic><topic>Drug Synergism</topic><topic>Female</topic><topic>General aspects</topic><topic>Glucose - pharmacology</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred Strains</topic><topic>Pharmacology. Drug treatments</topic><topic>Stimulation, Chemical</topic><topic>Verapamil - pharmacology</topic><topic>Verapamil - toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FRICHE, E</creatorcontrib><creatorcontrib>SKOVSGAARD, T</creatorcontrib><creatorcontrib>NISSEN, N. I</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FRICHE, E</au><au>SKOVSGAARD, T</au><au>NISSEN, N. I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>1987-01-01</date><risdate>1987</risdate><volume>19</volume><issue>1</issue><spage>35</spage><epage>39</epage><pages>35-39</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>Previous studies have demonstrated that verapamil may overcome resistance to anthracyclines. In vitro and in vivo experiments were performed on wild-type and resistant Ehrlich ascites tumor cells. Verapamil in concentrations of 25-50 microM enhances the accumulation of daunorubicin (DNR) in resistant cells to the same level as in wild-type cells. No significant effect of verapamil on influx or nuclear binding could be demonstrated, indicating that verapamil enhances DNR uptake by blocking active drug extrusion. Exposure of cells to a high concentration of Ca2+ did not influence the effect of verapamil on DNR accumulation, suggesting a different mode of verapamil action apart from the Ca2+-blocking effect. Attempts to circumvent acquired resistance to DNR in vivo with verapamil showed that the combination of the two drugs was more toxic than DNR given alone. The LD10 of DNR was determined as 3 mg/kg and the LD10 of the combination, as 2.5 mg/kg. The therapeutic effect of verapamil at a dose of 50 mg/kg and DNR of 2.5 mg/kg increased the life span of the mice by 50%. No difference was seen in the wild-type tumor in vivo. These data lead us to conclude that verapamil can reverse DNR resistance completely, but that verapamil at non-toxic dosage only reduces DNR resistance by 50% in vivo.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>3815723</pmid><doi>10.1007/BF00296252</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0344-5704
ispartof Cancer chemotherapy and pharmacology, 1987-01, Vol.19 (1), p.35-39
issn 0344-5704
1432-0843
language eng
recordid cdi_crossref_primary_10_1007_BF00296252
source SpringerLink Online Journals Archive Complete
subjects Animals
Antineoplastic agents
Biological and medical sciences
Biological Transport, Active - drug effects
Calcium - pharmacology
Carcinoma, Ehrlich Tumor - metabolism
Carcinoma, Ehrlich Tumor - pathology
Cell Line
Daunorubicin - metabolism
Daunorubicin - toxicity
Dose-Response Relationship, Drug
Drug Resistance
Drug Synergism
Female
General aspects
Glucose - pharmacology
Medical sciences
Mice
Mice, Inbred Strains
Pharmacology. Drug treatments
Stimulation, Chemical
Verapamil - pharmacology
Verapamil - toxicity
title Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T21%3A26%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20verapamil%20on%20daunorubicin%20accumulation%20in%20Ehrlich%20ascites%20tumor%20cells&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=FRICHE,%20E&rft.date=1987-01-01&rft.volume=19&rft.issue=1&rft.spage=35&rft.epage=39&rft.pages=35-39&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/BF00296252&rft_dat=%3Cpubmed_cross%3E3815723%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c311t-7c4ee81de0402541a02d37acae792e0ea2cf3203c83e450c98628e6e07eacc253%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/3815723&rfr_iscdi=true